Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Dropping the price
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(58)
•••
Comment by whisky11on Apr 23, 2021 2:27pm
119 Views
Post# 33056396

RE:RE:RE:Dropping the price

RE:RE:RE:Dropping the priceMick00333]Dude stfu piece of sh1t and learn how to read my post... i want the price to grow up and stop dropping it... better look your IQ before talking..

whisky11: which part of your post tells me that you want a price grow up?
People not dropping the price. Is the same like yesterday close.
You're talking about impossible disasters scenario.
I read it as a brainwash. You don't have to learn how to read mine post why we would have to learn special skills to read yours?

Mick00333 wrote:

...People are dropping the price, but what gonna happen when the price will reach 0.01 ?? they will cry because it cant goes up or the compagnie will bankcrup and everyone going to lose everything...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities